MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AdvaMed's Ubl Straightens Out NYT Device Coverage

In an opinion letter, Stephen Ubl, clarified a few things the New York Times has gotten wrong about devices in its recent coverage. Ubl, who is the president and CEO of AdvaMed, said that the Jan. 15 article “Report Criticizes F.D.A.

on Device TestingâEUR incorrectly characterized the device review process as "lax." In the published letter, Ubl says: FDAâEUR(TM)s premarket review process involves extensive review of specifications and performance-testing information, and in many cases clinical data, before being made available to patients. For the higher risk devices, FDA requires comprehensive clinical data for approval. The Government Accountability OfficeâEUR(TM)s report on FDAâEUR(TM)s review process, the focus of the article, limited its comments primarily to a small subset of 20 devices that the FDA has yet to classify, not the review process as a whole. In fact, the GAO report demonstrates that FDAâEUR(TM)s process is working as intended so that all devices are subject to the appropriate level of regulation to ensure their safety and effectiveness.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish